Burton Jodie M, O'Connor Paul
Multiple Sclerosis Clinic, Division of Neurology, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada.
Curr Neurol Neurosci Rep. 2007 May;7(3):223-30. doi: 10.1007/s11910-007-0034-2.
In 1993, interferon beta-1b, the first clinically proven disease-modifying agent for multiple sclerosis, was approved, with several comparable agents following close behind. These agents have been beneficial in reducing relapse events and MRI lesions, but all require parenteral administration, leading some otherwise eligible patients to decline such therapies. Oral agents have been studied for decades with mixed results, but a small number of medications currently being tested in phase II/III clinical trials have shown promise in efficacy and tolerability. This review assesses the results of the more thoroughly studied of these agents, some of which may soon be approved for use in multiple sclerosis.
1993年，首个经临床验证的用于治疗多发性硬化症的疾病修正药物——干扰素β-1b获得批准，随后有几种类似药物相继问世。这些药物在减少复发事件和磁共振成像（MRI）病灶方面具有益处，但均需肠胃外给药，这导致一些原本符合条件的患者拒绝接受此类治疗。口服药物已研究了数十年，结果不一，但目前正在进行II/III期临床试验的少数药物在疗效和耐受性方面已显示出前景。本综述评估了这些药物中研究更为深入的结果，其中一些药物可能很快会被批准用于治疗多发性硬化症。
